Improvements in 25 years of implantable cardioverter defibrillator therapy

Netherlands Heart Journal

Volumn 19, Issue 1, 2011, Pages 24-30

  van Welsenes, G H ^a   Borleffs, C J W ^a   van Rees, J B ^a   Atary, J Z ^a   Thijssen, J ^a   van der Wall, E E ^a   Schalij, M J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arrhythmia; Cardiac resynchronization therapy; Defibrillation; Implantable cardioverter defibrillator; Sudden death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EFFECTIVENESS; DEFIBRILLATION; DEFIBRILLATOR; DEVICE APPROVAL; ELECTRIC BATTERY; EQUIPMENT DESIGN; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH; SURVIVAL TIME;

EID: 79955438368     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-010-0047-3     Document Type: Review

References (28)

1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for manage- ment of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guide- lines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48:e247-346.
2. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhyth- mias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322-4.
3. Epstein AE, Dimarco JP, Ellenbogen KA, Estes III NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device- based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guidelineupdate forimplantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1-62.
4. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrilla- tors (AVID) Investigators. N Engl J Med. 1997;337:1576-83.
5. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a random- ized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.
6. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.
7. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52:1111-21.
8. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.
9. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30:1500-5.
10. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
11. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90.
12. Moss AJ, Fadl Y, Zareba W, Cannom DS, Hall WJ. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516-20.
13. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
14. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44:2166-72.
15. Wilde AA, Simmers TA. Primary prevention with ICDs, are we on the right track? Neth Heart J. 2009;17:92-4.
16. Bracke FA, Dekker LR, van der Voort PH, Meijer A. Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? Neth Heart J. 2009;17:107-10.
17. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De MT, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
18. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
19. Swerdlow CD, Friedman PA. Advanced ICD troubleshooting: part I. Pacing Clin Electrophysiol. 2005;28:1322-46.
20. Bardy GH, Troutman C, Poole JE, Kudenchuk PJ, Dolack GL, Johnson G, et al. Clinical experience with a tiered-therapy, multi- programmable antiarrhythmia device. Circulation. 1992;85:1689-98.
21. Holley LK. Development of device therapy for ventricular arrhythmias. Heart Lung Circ. 2007;16:162-9.
22. Kroll MW, Swerdlow CD. Optimizing defibrillation waveform for ICDs. J Interv Card Electrophysiol. 2007;18:247-63.
23. Cannom DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27:419-31.
24. Gradaus R, Breithardt G, Bocker D. ICD leads: design and chronic dysfunctions. Pacing Clin Electrophysiol. 2003;26:649-57.
25. van Dessel PF. The Sprint Fidelis lead fracture story: time to come to our senses? Neth Heart J. 2010;18:4-6.
26. Borleffs CJ, van Erven L, van Bommel RJ, van der Velde ET, van der Wall EE, Bax JJ, et al. Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Elec- trophysiol. 2009;2:411-6.
27. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol. 2005;45:2022-5.
28. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.